NEXWAY
26.1.2021 14:02:08 CET | Business Wire | Press release
Nexway , a leading software and service company for e-commerce and payments, is very excited to launch the latest features on its personalized growth platform Nexway Monetize , moving forward in its mission to expand the online footprint and sales potential of software vendors, games publishers and service providers across 140 countries around the world.
In today’s uncertain business environment, the e-commerce and payment leader is looking to leverage its best technologies to offer a seamless purchase experience, helping its clients to remain flexible in their strategic approach to e-commerce.
Nexway‘s teams are driving versatility, flexibility, and frictionless features to conquer new markets and expand into vertical sectors linked to customer monetization , subscriptions , and B2B sales management . Nexway also intends to continue growing thanks to its agility, expertise, and high level of the customer purchase experience.
"Customer experience is a constantly moving target, changing to meet customer needs, expectations, and evolution. Every customer has different needs and flexibility skills are crucial to adjust to situations and being able to effectively address such challenges. Being flexible with your customers is a top priority in the COVID-19 world ." comments Frédéric Ribau , Chief Technical Officer and Chief Product Officer at Nexway.
To meet these expectations and context, the Company has tuned its Nexway Monetize platform with new e-commerce features and payment capabilities.
NEXWAY MONETIZE NEW FEATURES RELEASED
1/ Nexway launches multiple pre-order options available right away on the Monetize platform. This feature is mostly aimed, but not limited, at gaming publishers , allowing to convert consumers before a product/game release, to create buzz, to offer exclusivity or bonuses to its community, or simply to test its product/game. Read more.
2/ Nexway announces the evolution of its subscription capabilities and launches its subscription trial extension. This feature is intended for digital product and service providers to offer consumers a subscription with a trial period, to be renewed and extended automatically into a standard paying subscription. The trial period will be a new period integrated into the subscription model, allowing the provider to define the duration of the trial period and switch it on or off depending on his will. Read more .
3/ Nexway expands its global payment services,
announcing a massive regional expansion of its payment capabilities and services.
Efficiently selling in different countries requires expertise and specific capabilities. Nexway Monetize simplifies commerce with powerful payment technology
and
helps its customers to process payments in local currencies with the most adapted payment methods worldwide.
- Monetize supports India and the Nordics countries with local currencies and regional preferred payment methods
- In addition to Brazil, Nexway reinforces its LATAM footprint
- A range of new currencies has been implemented on Nexway’s payment platform
- Payments in installments
are now available in Brazil
- Nexway enables its clients to provide local offline payment methods
4/ To help publishers to develop their reseller network and bring differentiation to its existing reseller portal offer , Nexway has developed automatic commissions on license renewals feature for resellers. The goal of this feature is to increase the loyalty of the resellers. Read more.
“Whether B2B or B2C, today’s customers have an ever-higher expectation of service. Our challenge is to optimize the experience of our customers and support them in creating a strong differentiation and competitive advantage within the digital economy. Throughout 2021, we plan to add new solutions and features to support commerce by allowing companies to expand across borders and verticals,” adds Frédéric Ribau .
Product Documentation: Nexway Monetize
Ready to enhance customer experience and boost your global sales potential! Discover Nexway Monetize: personalized e-commerce growth platform. GET STARTED NOW
ABOUT NEXWAY
Nexway SASU
is a leading e-commerce and payment player. Combining technology and managed services, Nexway helps online businesses scale, grow, and thrive. Nexway’s expertise in subscriptions, local payments, fraud prevention, and reseller management enables customers to transform their purchasing experience and accelerate sales. Founded in 2002 and headquartered in Paris–La Défense, France, Nexway has subsidiaries in the USA, Brazil, Italy, Spain, Poland, and Japan. Companies that rely on Nexway include FNAC-Darty™, Amazon™, Kaspersky™, Adobe™, Avast™, TakeTwo™, and hundreds more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005053/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
